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Introduction: Continuous renal replacement therapy (CRRT) has been widely used in critically ill acute kidney
injury (AKI) patients. Moreover, some centers operate a specialized CRRT team (SCT) composed of physicians and
nurses, but few studies have yet determined the superiority of SCT control.
Methods: A total of 334 among 534 patients in the original cohort, who started CRRT for severe AKI between
August 2007 and September 2009 in Yonsei University Health System and were matched with a propensity score
(PS), were divided into two groups based on SCT application. Moreover, we compared CRRT-related outcomes
including down-time per day and lost time per filter-exchange between the two groups. The primary outcomes
were 28- and 90-day all-cause mortality, and the secondary outcomes were the rates of renal function recovery
at 28- and 90-day.
Results: The down-time per day, lost time per filter-exchange, and red blood cell-transfused numbers during
CRRT treatment were significantly lower after SCT approach compared with the group before SCT, while net
ultrafiltration rate in the after SCT group was significantly higher compared to the before SCT group. During the
study period, the 28- and 90-day all-cause mortality rates were significantly decreased after SCT application. Cox
regression analysis revealed that 28- and 90-day all-cause mortality rates were significantly lower under SCT
control, after adjusting for primary diagnosis, emergent surgical cases, Charlson Comorbidity Index and biochemical
parameters. However, there were no significant differences in the rate of renal function recovery before and after
SCT approach in CRRT.
Conclusions: A well-organized CRRT team could be beneficial for clinical outcomes through improving quality of
care in AKI patients requiring CRRT treatment in the ICU.Introduction
Severe acute kidney injury (AKI) is a well-recognized
complication in critically ill patients and has a substan-
tial impact on morbidity, mortality, and health resource
utilization in this population [1-5]. Although only con-
servative treatment such as fluid and hemodynamic
optimization was provided for critically ill patients with* Correspondence: yoosy0316@yuhs.ac
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unless otherwise stated.severe AKI in the past [6], continuous renal replacement
therapy (CRRT) has recently been an integral part of
critical care and is considered an established treatment
modality for AKI patients [7]. Even though recent ad-
vances in technical devices have widened clinical indica-
tions for CRRT, the mortality rate in this population still
remains extremely high [8-10]. Given the complexity of
treating AKI patients and handling the extracorporeal
system, highly efficient CRRT management, which in-
cludes proper exchange of extracorporeal circuits, fre-
quent monitoring for dose of CRRT, and optimal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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ded as potential candidates for improving patient out-
comes [9,11].
It has been speculated that repeated quality control is
essential to obtain optimal management of CRRT.
Therefore, some centers operate specialized CRRT teams
(SCT) with physicians and nurses from their disciplines
[12]. It might be suggested that the survival rates of the
patients after care by the SCT would be superior; however,
to our knowledge, only one study has been reported on
the comparison before and after the SCT approach [12].
Moreover, several factors, including patients’ severity
scores, make it difficult to clarify the benefit of SCT man-
agement. We initiated the SCT approach for the manage-
ment of CRRT in 2008, and thus we can compare the
outcomes and quality of CRRT management before and
after the SCT approach. In addition, we used propensity
score (PS) matching to investigate the benefit of SCT
management for 28- and 90-day all-cause mortalities
and renal function recovery in AKI patients undergo-
ing CRRT.
Methods
Patients
A total of 682 patients who started CRRT for severe AKI
between August 2007 and September 2009 were initially
analyzed. We excluded 148 patients because they were
below 18 years of age, were on chronic dialysis, or were di-
agnosed with terminal malignancy with less than 3 months
of life expectancy. Therefore, 534 patients were included
in the final analysis (Figure 1).
The study protocol was approved by the Institutional
Review Board (IRB) of the Yonsei University HealthFigure 1 Flow diagram of patient selection and outcomes. From Augu
the groups before and after SCT, respectively. After 1:1 propensity score ma
was ultimately analyzed. SCT, specialized continuous renal replacement the
score.System (YUHS) Clinical Trial Center. As this study was
a retrospective medical record-based study and the study
subjects were de-identified, the IRB waived the need for
written consent from the patients.
Data collection
Patients’ data were retrieved from the CRRT Database of
YUHS, Seoul, Korea. Demographic, clinical, and bio-
chemical data at the time of admission to the ICU and
CRRT initiation were recorded. For the assessment of
disease severity, the sequential organ failure assessment
(SOFA) score and acute physiology and chronic health
evaluation (APACHE) II score were determined at the
start of CRRT.
We counted the transfused number of packed red
blood cells (RBC) during the period of CRRT treatment
except for transfusions conducted due to active bleeding.
Such active bleeding is considered to be in a situation
where the patients need a transfusion of more than 10
units of packed RBC within 24 hrs or are bleeding more
than 1- to 1.5-fold of the body’s entire blood volume as
previously described [13]. Down-time (hours/day) was
defined as the period of time when CRRT was not ap-
plied between initiation and end of CRRT, as defined by
Uchino [14].
SCT approach
An SCT was set up in August 2008 in our hospital, and
thus we can compare clinical outcomes before and after
the SCT approach. The SCT is defined as a team of
physicians and nurses, who are specially trained and
educated to perform CRRT. The members of the SCT
include two specialized nephrologists, two nephrologyst 2007 through September 2009, we enrolled 295 and 387 patients in
tching, each of the 167 patients before and after the SCT approach
rapy team; CRRT, continuous renal replacement therapy; PS, propensity
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CRRT specialized nurses. They create and share the
educational programs and management protocol on
CRRT. In addition, monthly quality control is performed
to correct management protocols and problems with
CRRT, such as electrolytes, coagulation, and hemody-
namic status. Moreover, we have adopted and used the
anticoagulation protocol, which was suggested from
Bagshaw et al. [15]. Members of the SCT team have
complementary roles to each other. ICU specialist and
residents have a primary responsibility for general patient
care and make overall decisions about the medical
problems of ICU patients. Especially, nephrologists are
authorized to initiate, maintain and stop CRRT and switch
to intermittent hemodialysis or peritoneal dialysis. They
decide whether to start CRRT based on the patient’s
hemodynamic status, declining urine output, and electro-
lyte and acid-base imbalances and also decide the mode
and dose of CRRT, and net ultrafiltration rate during
CRRT. In the nursing section, CRRT-nurses work three
shifts daily. They monitor the patients treated with CRRT
on the ICU at regular intervals, and check hemodynamic
stability, the removal rate of real ultrafiltration, and the
status of the CRRT kit, et cetera. Their primary role is
CRRT management apart from the ICU general care,
which is performed by bedside nurses. In addition, they
also provide education for basic CRRT-handling methods
to bedside nurses every three months. Half of the CRRT
nurses rotate among the ICU nurses every year. Based on
daily rounds with the specialized team, they discuss and
try to solve potential problems with management of CRRT
(Figure 2). Additional tables show these descriptions in
more detail (See Additional file 1: Tables 1 and 2).
ICU setting
The investigation site was a self-contained, 112-bed
medical and surgical ICU in a 2,089-bed teaching hos-
pital in Seoul, Korea that was equipped with 15 CRRT
machines. The ICU unit is a closed structure within this
hospital. There was no difference in the determination
of CRRT treatment according to decisions made by the
same nephrologist before and after SCT. On the con-
trary, bedside nurses cared for their ICU patients at a
ratio of two patients per nurse, but they also had to
perform monitoring and maintenance of the CRRT
system before SCT set-up. However, after the introduction
of the SCT approach, additional nursing care was available
for CRRT care.
CRRT protocol
Vascular access for CRRT was obtained via the internal
jugular, femoral, or subclavian vein. In most patients,
continuous veno-venous hemodiafiltration, including
slow continuous ultrafiltration, was performed usingthe PRISMA (Gambro, Hechingen, Germany) platform.
CRRT was initiated at a blood flow rate of 100 mL/mi-
nute, which was gradually increased to 150 mL/minute.
The ultrafiltration dose was set at 35 mL/kg/hr, and
Hemosol® (Gambro) was replaced by the predilution
method. We also measured the delivered drainage amount
and recorded it to calculate the delivered CRRT dose
daily. Circuit exchanges were conducted regularly after
48 hrs of use, even if the blood pumps were not stopped.
Statistical analysis
This study was a matched cohort study using two groups
of patients before and after SCT management to analyze
the effect of several potential confounders. The patients
were matched 1:1 by PS using the greedy matching algo-
rithm (eight- to one-digit match) [16]. Once the group
of patients before SCT was matched, the patients after
SCT were not reconsidered. The algorithm made the
best matches first and next-best matches second in a
hierarchical sequence until no additional matches could
be made. Best matches were those with the highest digit
match on PS. First, patients in the group before SCT
were matched to patients in the group after SCT on
eight digits of the PS. For those that did not match, pa-
tients from the group before SCT were then matched to
patients after SCT based on seven digits of the PS. The
algorithm proceeded sequentially to the lowest digit
match on PS (one digit). We derived the PS from a
multi-logistical regression model with the following vari-
ables: age, gender, mean arterial pressure (MAP), SOFA
and APACHE II scores, and risk, injury, failure, loss, and
end kidney disease (RIFLE) criteria. After all PS matches
were performed, we assessed the balance in baseline co-
variates between the two groups using the Wilcoxon
signed rank test for continuous variables and the McNe-
mar test for categorical variables. PS matching was con-
ducted using SAS version 9.1 (SAS Institute, Cary, NC,
USA). We also presented original data before PS match-
ing and compared clinical outcomes between the before-
SCT and after-SCT groups in both original and matched
cohorts, respectively.
Continuous variables are presented as mean ± SD and
categorical variables as numbers and percentages, if they
were statically normally distributed. Moreover, they were
compared using the Student t-test for continuous vari-
ables and the χ2 test for categorical variables. However,
medians and interquartile ranges are presented unless
variables are clearly normally distributed, and they were
compared using Mann-Whitney test. In the present
study, we evaluated 28- and 90-day all-cause mortalities
as primary endpoints. We also compared the proportion
of patients with renal function recovery, which was de-
fined based on creatinine clearance (≥15 mL/minute)
with no need of renal replacement therapy at 28- and
Figure 2 Flow diagram of programmed SCT management of vascular access. When CRRT starts, SCT monitors circuit pressure (arterial,
venous, and transmembrane) every 8 hrs. Extracorporeal circuit exchanges are conducted according to appointed protocols for access
management. SCT, specialized continuous renal replacement therapy team; CRRT, continuous renal replacement therapy.
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endpoints.
Survival curves were designed using the Kaplan-Meier
method, and comparisons were made using the log-rank
test. The impact of SCT control on 28- and 90-day mor-
talities in AKI patients treated with CRRT was deter-
mined using the Cox proportional hazards model, and
the results are presented as hazard ratios (HRs) and 95%
CIs. To confirm the assumption of proportionality, time-
dependent covariate analysis was used, and it was not
statistically significant, suggesting that the proportional
hazards assumption was reasonable. All tests were two-
sided, and P <0.05 was considered significant. Statistical
analyses were performed with SPSS for Windows, version
18.0 (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics in both original and matched
groups
Baseline characteristics of these patients are shown in
Table 1. In the original cohort, the proportion of male
patients was significantly higher in the after-SCT group
compared with the before-SCT group (68.2% versus
58.7%, P = 0.028), while APACHE II score and SOFA
score were significantly lower in the after-SCT group
compared to the before-SCT group (APACHE II score;
26.9 versus 28.4, P = 0.029 and SOFA score; 11.9 versus
14.2, P = 0.031). However, there were no significant dif-
ferences in age, MAP, age-adjusted CCI, RIFLE status,
contributing factors for AKI, primary diagnosis, emer-
gent surgical cases, use of anticoagulation and diuretics,or biochemical parameters, between the two groups. The
1:1 PS matching yielded matched pairs of 167 patients in
the before-SCT group and 167 patients in the after-SCT
group, resulting in no differences in the above-mentioned
variables.
Comparisons of clinical outcomes and renal outcomes in
original and matched groups during follow up
The down-time per day, lost time per filter-exchange,
RBC-transfused numbers, and the transfusion rates dur-
ing CRRT treatment were significantly lower after the
SCT approach compared to in group before SCT in both
cohorts, while net ultrafiltration rate in the after-SCT
group was significantly higher compared to that in the
before-SCT group. However, total CRRT time was sig-
nificantly lower under SCT in both cohorts, whereas the
median filter lifespan during the CRRT treatment was
significantly higher after the SCT approach compared
with the group before SCT only in original cohort
(Table 2). On the contrary, there were no significant dif-
ferences in the proportions of living patients with renal
function recovery at 28-day and 90-day intervals be-
tween the two groups in both original and matched
cohorts (Table 3). Moreover, vasoactive drugs such as
dopamine and norepinephrine were required in 390 pa-
tients (73.0%), who were 166 patients (74.4%) in the
before-SCT group and 224 patients (72.0%) in the SCT
group before CRRT start. Ten days after CRRT applica-
tion, 21 patients of 83 survivors in the before-SCT group
and 26 patients of 106 survivors in the after-SCT group
continuously received vasoactive drugs, and there was
Table 1 Baseline characteristics at CRRT initiation in the original and the matched cohort
Variables Original cohort P-value Matched cohort P-value
Before SCT
(n = 223)
After SCT
(n = 311)
Before SCT
(n = 167)
After SCT
(n = 167)
Age, years 62.8 ± 14.0 61.6 ± 15.1 0.350 63.2 ± 13.6 63.1 ± 15.1 0.961
Male, n (%) 131 (58.7%) 212 (68.2%) 0.028 99 (59.3%) 99 (59.3%) >0.999
Mean arterial pressure, mmHg 80.7 ± 17.3 78.7 ± 16.0 0.168 80.7 ± 17.5 79.9 ± 15.2 0.881
APACHE II score 28.4 ± 8.6 26.1 ± 7.0 0.029 27.6 ± 8.1 27.4 ± 6.9 0.783
Sequential organ failure assessment score 14.2 ± 3.9 11.9 ± 3.4 0.031 12.1 ± 2.8 12.1 ± 3.3 0.958
Age-adjusted Charlson comorbidity index 6.1 ± 3.5 5.7 ± 3.0 0.365 5.9 ± 3.1 5.7 ± 2.8 0.886
RIFLE, n (%) 0.647 0.901
Risk 96 (43.1%) 140 (45.0%) 75 (44.9%) 75 (44.9%)
Injury 79 (35.4%) 108 (34.7%) 56 (33.5%) 59 (35.3%)
Failure 48 (21.5%) 63 (20.3%) 36 (21.6%) 33 (19.8%)
Contributing factors, n (%) 0.681 0.849
Sepsis 112 (50.2%) 158 (50.8%) 87 (52.1%) 88 (52.7%)
Hemodynamic instability without sepsis 84 (37.7%) 106 (34.1%) 55 (32.9%) 51 (30.5%)
Major surgery 27 (12.1%) 47 (15.1%) 25 (15.0%) 28 (16.8%)
Use of anticoagulation, n (%) 179 (80.3%) 235 (75.6%) 0.209 129 (77.2%) 128 (76.6%) 0.891
Diuretics use, n (%) 178 (79.8%) 246 (79.1%) 0.831 129 (77.2%) 128 (76.6%) 0.787
Biochemical data
Hemoglobin, g/L 92 ± 18 92 ± 18 0.987 92 ± 18 92 ± 19 0.837
Whole blood cells, 103/mm3 15.6 ± 12.2 14.1 ± 10.5 0.174 15.2 ± 12.0 14.5 ± 11.0 0.577
Blood urea nitrogen, mmol/L 20.2 ± 9.5 19.0 ± 10.4 0.166 20.7 ± 9.8 18.7 ± 10.0 0.066
Creatinine, umol/L 300.6 ± 167.9 309.4 ± 203.3 0.681 318.2 ± 176.8 300.6 ± 185.6 0.393
Total cholesterol, mmol/L 95.2 ± 45.5 92.3 ± 43.4 0.495 95.5 ± 45.9 91.6 ± 41.3 0.411
Albumin, g/L 26 ± 6 27 ± 6 0.209 26 ± 6 28 ± 6 0.106
C-reactive protein, mg/L 14.3 ± 12.0 12.4 ± 12.7 0.106 14.4 ± 11.9 12.8 ± 11.2 0.300
Arterial pH 7.4 ± 0.1 7.3 ± 0.4 0.174 7.3 ± 0.1 7.3 ± 0.5 0.080
Total bilirubin, umol/L 68.4 ± 123.1 63.3 ± 109.4 0.602 66.7 ± 119.7 63.3 ± 100.9 0.814
HCO3
−, mmol/L 19.9 ± 4.9 19.2 ± 5.5 0.157 20.0 ± 4.8 19.1 ± 5.7 0.125
Data are presented as n (%) or mean ± SD. CRRT, continuous renal replacement therapy; SCT, specialized CRRT team; APACHE II, acute physiology and chronic
health evaluation II; RIFLE, risk, injury, failure, loss, and end kidney disease.
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vasoactive medications.
SCT approach is independently associated with survival in
AKI patients
In the original cohort, 28- and 90-day all-cause mortality
was significantly higher in the group before SCT com-
pared to in the group after SCT (69.1% versus 49.8%,
P = 0.013 and 76.2% versus 60.1%, P = 0.026, respectively).
These findings were also consistent in the matched cohort
(before-SCT group versus after-SCT group; 62.3% versus
48.5%, P = 0.015 for 28-day all-cause mortality, and 70.7%
versus 59.3%, P = 0.039 for 90-day all-cause mortality, re-
spectively). In addition, Kaplan Meier plots demonstrated
that 28- and 90-day all-cause mortality was significantly
higher in the group before SCT (P = 0.028 for 28-day andP = 0.033 for 90-day mortality, respectively) (Figure 3).
Cox regression analysis revealed that 28- and 90-day
all-cause mortality rates were significantly reduced
after SCT (HR 0.643; 95% CI 0.470, 0.879; P = 0.006
for 28-day and HR 0.680; 95% CI 0.510, 0.906; P = 0.008
for 90-day mortality) (model 1). Moreover, the lower
mortality risk in the group on SCT remained signifi-
cant even after adjusting for model 1 plus Hb, serum
albumin, total cholesterol, and C-reactive protein (CRP)
levels (HR 0.720; 95% CI 0.540, 0.968; P = 0.027 for 28-day
and HR 0.742; 95% CI 0.570, 0.988; P = 0.039 for 90-day
mortality) (model 2). Furthermore, adjustments for model
2 plus primary diagnosis, emergent surgical cases and age-
adjusted CCI did not change the benefit for primary
outcomes of the SCT approach (HR 0.897; 95% CI
0.681, 0.982; P = 0.040 for 28-day mortality and HR 0.927;
Table 2 Study outcomes and parameters associated with CRRT in groups of patients before and after SCT in both cohorts
Unmatched cohort P-value Matched cohort P-value
Before SCT
(n = 223)
After SCT
(n = 311)
Before SCT
(n = 167)
After SCT
(n = 167)
Total CRRT time, days 7 (1 to 48) 4 (1 to 34) 0.023 5 (1 to 48) 4 (1 to 32) 0.197
Down-time per day, hrs 5.2 (3.7-16.5) 3.1 (2.5 to 5.9) <0.001 4.8 (3.7 to 9.4) 3.3 (2.8 to 5.7) <0.001
Lost time per filter-exchange, minutes 43 (28 to 57) 25 (20 to 32) <0.001 42 (31 to 55) 23 (20 to 30) <0.001
Ultrafiltration rate, mL/kg/hr 22.5 (19.8 to 28.1) 27.1 (25.1 to 30.5) 0.031 24.5 (22.5 to 28.1) 28.2 (26.3 to 30.5) 0.039
Number of TF during CRRT 9 (1 to 22) 7 (1 to 17) 0.028 8 (1 to 22) 6 (1 to 14) 0.021
TF rate, n (%) 165 (74.0%) 208 (66.9%) 0.039 118 (70.7%) 106 (63.5%) 0.043
Filter life span, hrs 22.0 (5.9 to 44.1) 29.4 (6.1 to 40.1) <0.001 25.7 (5.9 to 43.8) 31.1 (6.1 to 39.7) 0.084
CRRT mortality, n (%)
28 days 154 (69.1%) 155 (49.8%) 0.013 104 (62.3%) 81 (48.5%) 0.015
90 days 170 (76.2%) 187 (60.1%) 0.026 118 (70.7%) 99 (59.3%) 0.039
Data are presented as n (%) and median and interquartile ranges. CRRT, continuous renal replacement therapy; SCT, specialized CRRT team; TF, transfusions;
ICU, intensive care unit.
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(model 3) (Table 4).
Discussion
In this study, we found that the SCT approach for man-
aging CRRT reduced 28- and 90-day mortality rates in
AKI patients. These findings suggest that well-trained
and well-organized team approaches have a beneficial
effect on clinical outcomes in AKI patients treated with
CRRT in the ICU.
CRRT has been preferred for AKI patients with he-
modynamic instability to control uremia, electrolytes,
acid-base status, and volume balance in many ICUs [9].
Although there is still controversy about the optimal
dose of CRRT, the minimal required dose is necessary
for adequate solute control and the correction of electro-
lyte and acid-base imbalance; however, frequent blood-
pump halting and prolonged manipulation time for the
replacement of tubing systems can result in inadequate
treatment doses and blood loss in these patients [17,18].
Uchino et al. [14] reported that the median down-time
was 3.0 hrs (1.0 to 8.3), thus, concluded that the term,
continuous, in CRRT is somewhat inaccurate due to
frequent interruptions in CRRT treatment. They also
suggested that down-time adversely affected azotemic
control, and therefore physicians who prescribe CRRT
should be aware of the consequences of such down-Table 3 Comparison of renal function recovery among surviv
Variables Original cohort
Before SCT After SCT
Recovery of renal function, n (%)*
28 days 47/69 (68.1%) 109/156 (69.9%
90 days 47/53 (88.7%) 111/124 (89.5%
Data are presented as number/total number (%). SCT, specialized continuous renal
creatinine clearance (≥15 mL/minute) with no need for renal replacement therapy.time on the quality and quantity of renal replacement
therapy [14]. A previous clinical trial, including a multi-
national observational study by Vesconi et al. [19], also
showed a wide variability in ultrafiltration rates with large
differences between the prescribed and delivered doses,
which was mainly due to circuit down-time [14,20-22].
The patients treated with CRRT are essentially immobile,
frequently have to be sedated, and can develop hypo-
thermia [23]. Moreover, a large number of patients have
disseminated intravascular coagulation. Therefore, extra-
corporeal circuits are prone to clotting in most of the
patients [23]. Apart from clotting in the extracorporeal
circulation, vascular access problems frequently occur.
Taken together, access problems and thrombogenecity re-
duce the circuit lifetime in this population [23]. Frequent
interruptions of CRRT due to extracorporeal circuit failure
inevitably increase CRRT down-time and are also associ-
ated with blood loss, requiring multiple blood transfusions
[24], and increasing costs [23]. Especially, AKI patients
requiring CRRT treatment are mostly susceptible to
fluid balance. If the longer CRRT down-time persists,
the more fluid removal will be needed during the
remaining time in order to overcome volume overload.
Fast removal of fluid by net ultrafiltration may lead to
sympathetic over-activity and harmful effects on the myo-
cardium, and increase the risk of hypoperfusion to vital
organs [25,26].ors in the original and matched cohorts
P-value Matched cohort P-value
Before SCT After SCT
) 0.663 42/63 (66.7%) 60/86 (69.8%) 0.592
) 0.779 44/49 (89.8%) 61/68 (89.7%) 0.866
replacement therapy team. *Recovery of renal function was defined based on
Figure 3 Kaplan-Meier plots for cumulative 28- and 90-day mortality. The 28- and 90-day all-cause mortality rates after the SCT approach
were significantly lower; log rank P = 0.028 (A) and P = 0.033 in (B). SCT, specialized continuous renal replacement therapy team.
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filter-exchange, and numbers of RBC transfused during
CRRT were significantly reduced after the SCT approach
compared with the group before SCT. In addition, the
28- and 90-day mortality rates in the after-SCT group
were significantly lower compared with the before-SCT
group. Taken together, we surmise that decreased down-
times, lost time per filter-exchange, and numbers of RBC
transfused should play indispensable roles to reduce the
mortality in AKI patients requiring CRRT.
Still, the gaps in down-time and RBC transfusion
requirements are not enough to explain the difference in
CRRT mortality between the two groups. Gilbert et al.
[12] demonstrated that the CRRT program definitely
enhanced the level of care given to patients by allowing
the bedside nurse on general patient care into the ICU.
At the same time, the trained CRRT-nurse could con-
centrate solely on CRRT, thereby providing an additional
level of care. For these reasons, they demonstrated thatTable 4 Cox proportional hazards models for 28- and
90-day mortality in the SCT group
Compared with before SCT management
Mortality at 28 days Mortality at 90 days
HR 95% CI P-value HR 95% CI P-value
Model 1 0.643 0.470, 0.879 0.006 0.680 0.510, 0.906 0.008
Model 2 0.720 0.540, 0.968 0.027 0.742 0.570, 0.988 0.039
Model 3 0.897 0.681, 0.982 0.040 0.927 0.725, 0.997 0.042
Model 1: unadjusted hazard ratio; model 2: Model 1 with additional
adjustments for hemoglobin, serum albumin, total cholesterol, and C-reactive
protein levels; Model 3: model 3 with primary diagnosis, emergent surgical
procedure and age-adjusted Charlson comorbidity index. CRRT, continuous
renal replacement therapy; SCT, specialized CRRT team; HR, hazard ratio.mortality rates in the CRRT program might be lower
than expected, especially in critically ill burn patients
[12]. Taken together, we suggest that the beneficial effects
of the SCT approach could result from adequate applica-
tion of management protocols, appropriate monitoring
and exchange of CRRT, and frequent assessment and opti-
mal troubleshooting in CRRT management.
Our study has several potential limitations that should
be noted. First, this was an observational study in which
the effect of confounding by indication could not be fully
excluded. Some important baseline covariates were not
distributed equally and many confounding factors, includ-
ing the severity score, usually affect patient outcomes in
this population. In the original cohort, the proportion of
male patients was significantly lower in the before-SCT
group than in the after-SCT group, whereas APACHE II
and SOFA scores were significantly higher in the before-
SCT group compared to the after-SCT group, which might
lead to potential bias. Using PS matching, an identical,
matched cohort at baseline between the two groups was
created. However, a prospectively planned cluster or
stepped wedge trial at multiple centers could be more
helpful to evaluate the impact of an SCT in the future.
Second, the two groups before and after the SCT
approach were not conducted at the same time. There-
fore, there might be differences in the treatment trends
during the study periods; however, the gap between the
periods was only 1 year; also, the same ICU policy was
applied to the patients in a single center, the patients
in this study experienced no differences in ICU care,
such as the decision-making process for CRRT, and
there were few missing datasets. Moreover, as shown
in Table 1, there were no significant differences in the
Oh et al. Critical Care 2014, 18:454 Page 8 of 9
http://ccforum.com/content/18/1/454baseline characteristics between the two groups after PS
matching. Therefore, the bias caused by the different time
periods may be overcome.
Third, the mortality rates of our patients were some-
what higher compared with those in previous studies of
patients with AKI treated with CRRT [27]. However,
Allegretti et al. [8] reported that in-hospital mortality
was 61% for AKI patients requiring CRRT, and AKI with
the same SOFA score contributed to a higher mortality
rate. In addition, the severity of disease assessed by
APACHE II and SOFA scores and age-adjusted CCI in
this present study were somewhat higher compared with
those of previous studies. Taken together, exceptionally
high mortality rates could be expected, considering these
patients had higher SOFA scores and needed CRRT. On
the contrary, we examined the mortality rates at 28 and
90 days for all admissions to this ICU and for other
common diagnoses (namely, sepsis, trauma, cardiac sur-
gery, cardiovascular origin et cetera) during the follow-
up period. With the exclusion of pediatric patients and
patients who took one-day elective ICU admission after
a procedure, survival rates during the follow up period
were analyzed for a total of 6,222 patients. Sepsis in
1,901 patients (30.6%) was the most common diagnosis
in the meantime. The 28- and 90-day all-cause mortality
rates after SCT was set up were somewhat higher com-
pared with those before SCT was established, but the
differences were not statistically significant (P = 0.081
and 0.113, respectively). In the same way, there were no
significant differences in 28- and 90-day mortality rates
for each diagnosis between the two follow-up periods
when we classified the patients according to common
diagnoses (See Table 3 in Additional file 1). Despite
these limitations, to our knowledge, this study may be
the first report clarifying the impact of SCT control in
the clinical outcomes of patients undergoing CRRT.
Conclusions
A well-trained CRRT team could be beneficial for clinical
outcomes through improving quality of care in AKI
patients requiring CRRT in the ICU.
Key messages
 A well-organized CRRT team could be beneficial
for clinical outcomes through improving quality of
care in AKI patients requiring CRRT in the ICU.
 This study aimed to compare the benefit of SCT
by PS matching to overcome the differences from
unbalanced distribution in the original cohort.
 The down-time per day, lost time per
filter-exchange, and numbers of RBC transfused
during CRRT were significantly lower after the SCT
approach compared with the group before SCT,while the ultrafiltration rate in the after-SCT group
was significantly higher compared to the before-SCT
group. Moreover, the 28- and 90-day all-cause
mortality rates were significantly decreased after
SCT application.
Additional file
Additional file 1: Table S1. The modules of the educational program
for specialized continuous renal replacement therapy (CRRT) team (SCT)
nurses. Table S2. The protocol for replacement of electrolytes and
anticoagulation during CRRT. Table S3. The mortality rates at 28 and
90 days for all admissions to this ICU.
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